Cargando…

Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer

Breast cancer is the most commonly diagnosed cancer (estimated 2.3 million new cases in 2020) and the leading cause of cancer death (estimated 685,000 deaths in 2020) in women globally. Breast cancers have been categorized into four major molecular subtypes based on the immunohistochemistry (IHC) ex...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Chenyi, Wang, Peipei, He, Siqi, Zhu, Jingjing, Shi, Yuanyuan, Wang, Jianxun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9251310/ https://www.ncbi.nlm.nih.gov/pubmed/35795050 http://dx.doi.org/10.3389/fonc.2022.919072

Ejemplares similares

Prospects of Immunotherapy for Triple-Negative Breast Cancer
por: Qiu, Dan, et al.
Publicado: (2022)

Case Report: Response to Immunotherapy and Anti-Androgen Therapy in Male Occult Triple-Negative Breast Cancer
por: Wang, Xin-Hua, et al.
Publicado: (2022)

Development and validation of an inflammatory response-related signature in triple negative breast cancer for predicting prognosis and immunotherapy
por: Guo, Yangyang, et al.
Publicado: (2023)

Facts and Perspectives: Implications of tumor glycolysis on immunotherapy response in triple negative breast cancer
por: Schreier, Ashley, et al.
Publicado: (2023)

Ferroptosis and triple-negative breast cancer: Potential therapeutic targets
por: Xu, Na, et al.
Publicado: (2022)

The Heparan Sulfate Binding Peptide in Tumor Progression of Triple-Negative Breast Cancer
por: Melo, Carina Mucciolo, et al.
Publicado: (2021)

Correlation between the Warburg effect and progression of triple-negative breast cancer
por: Liu, Shaojun, et al.
Publicado: (2023)

Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer
por: Mediratta, Karan, et al.
Publicado: (2020)

Metabolic Reprogramming in Triple-Negative Breast Cancer
por: Sun, Xiangyu, et al.
Publicado: (2020)

Platinum-Based Chemotherapy and Immunotherapy in Early Triple-Negative Breast Cancer: A Meta-Analysis and Indirect Treatment Comparison
por: He, Qin, et al.
Publicado: (2021)

SENP3 promotes tumor progression and is a novel prognostic biomarker in triple-negative breast cancer
por: Zhu, Youzhi, et al.
Publicado: (2023)

SIPL1, Regulated by MAZ, Promotes Tumor Progression and Predicts Poor Survival in Human Triple-Negative Breast Cancer
por: He, Juanjuan, et al.
Publicado: (2021)

Immunotherapy for Triple-Negative Breast Cancer
por: Cao, Yifeng, et al.
Publicado: (2021)

Identification of Key Genes Affecting the Tumor Microenvironment and Prognosis of Triple-Negative Breast Cancer
por: Yi, Jiarong, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
por: Thomas, Remy, et al.
Publicado: (2021)

Research progress on immunotherapy in triple-negative breast cancer (Review)
por: Zhang, Xiaoxiao, et al.
Publicado: (2022)

Nanomaterial Technology and Triple Negative Breast Cancer
por: Hou, Kai, et al.
Publicado: (2022)

Salvia chinensis Benth Inhibits Triple-Negative Breast Cancer Progression by Inducing the DNA Damage Pathway
por: Wang, Kai-nan, et al.
Publicado: (2022)

Tumor-Associated Macrophages: Key Players in Triple-Negative Breast Cancer
por: Qiu, Xia, et al.
Publicado: (2022)

Protein Tyrosine Kinase 7 Regulates EGFR/Akt Signaling Pathway and Correlates With Malignant Progression in Triple-Negative Breast Cancer
por: Cui, Nai-Peng, et al.
Publicado: (2021)

Chidamide Reverses Fluzoparib Resistance in Triple-Negative Breast Cancer Cells
por: Li, Xinyang, et al.
Publicado: (2022)

Nomogram for Predicting Lymph Node Involvement in Triple-Negative Breast Cancer
por: Cui, Xiang, et al.
Publicado: (2020)

Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy
por: Yang, Ruoning, et al.
Publicado: (2022)

Targeted Therapeutic Strategies for Triple-Negative Breast Cancer
por: Li, Ying, et al.
Publicado: (2021)

Rewiring of the Endocrine Network in Triple-Negative Breast Cancer
por: Li, Kaixuan, et al.
Publicado: (2022)

Capecitabine-based chemotherapy in early-stage triple-negative breast cancer: a meta-analysis
por: Bai, Jie, et al.
Publicado: (2023)

High Throughput Transcriptome Data Analysis and Computational Verification Reveal Immunotherapy Biomarkers of Compound Kushen Injection for Treating Triple-Negative Breast Cancer
por: Liu, Xinkui, et al.
Publicado: (2021)

Resveratrol Mediates the Apoptosis of Triple Negative Breast Cancer Cells by Reducing POLD1 Expression
por: Liang, Zhi-Jie, et al.
Publicado: (2021)

Research Progresses in Immunological Checkpoint Inhibitors for Breast Cancer Immunotherapy
por: Zhang, Wenxiang, et al.
Publicado: (2021)

Identification of immunosuppressive signature subtypes and prognostic risk signatures in triple-negative breast cancer
por: Ding, Ran, et al.
Publicado: (2023)

Immunogenic Cell Death-Relevant Damage-Associated Molecular Patterns and Sensing Receptors in Triple-Negative Breast Cancer Molecular Subtypes and Implications for Immunotherapy
por: Xu, Ming, et al.
Publicado: (2022)

Global research trends on anti-PD-1/anti-PD-L1 immunotherapy for triple-negative breast cancer: A scientometric analysis
por: Wu, Jinyao, et al.
Publicado: (2023)

Progress: Targeted Therapy, Immunotherapy, and New Chemotherapy Strategies in Advanced Triple-Negative Breast Cancer
por: Shi, Jinhong, et al.
Publicado: (2020)

Immunotherapy Treatment for Triple Negative Breast Cancer
por: Berger, Elizabeth R., et al.
Publicado: (2021)

Immunotherapy for the Treatment of Triple-Negative Breast Cancer
por: Tolaney, Sara M., et al.
Publicado: (2022)

Advances in immunotherapy for triple-negative breast cancer
por: Liu, Yang, et al.
Publicado: (2023)

Multimodality MRI radiomics analysis of TP53 mutations in triple negative breast cancer
por: Sun, Kun, et al.
Publicado: (2023)

High Expression of microRNA-223 Indicates a Good Prognosis in Triple-Negative Breast Cancer
por: Chen, Li, et al.
Publicado: (2021)

Key Players in Choline Metabolic Reprograming in Triple-Negative Breast Cancer
por: Iorio, Egidio, et al.
Publicado: (2016)

Hyperoxygenation as a Therapeutic Supplement for Treatment of Triple Negative Breast Cancer
por: Mast, Jesse M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_93jtsq2aq9qsantqbrhihhjdvp